beta

POAI

Predictive Oncology Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

predictive oncology (nasdaq: poai) is focused on the use of data and artificial intelligence (ai) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcome. the company has several tools that support its mission of bringing precision medicine to the diagnosis of cancer. through its subsidiaries, predictive oncology’s portfolio of assets includes the following: - a database of clinically validated historical and outcome data from patient tumors - an in-house clinical laboratory improvement amendments (clia)-certified lab - a “smart” patient-derived tumor profiling platform - an in-house bioinformatics artificial intelligence (ai) platform - a new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options - an fda-approved fluid collection and disposal system using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries

Market Cap: 11.4 Million

Primary Exchange: NASDAQ

Website: http://www.precisiontherapeutics.com

Shares Outstanding: 4.06 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 2.7057322163783515

Sector: Manufacturing

Industry: Surgical and Medical Instrument Manufacturing

Ethical Flags

Longest drawdown: 377 trading days

From: 2019-10-04 To: 2023-06-27

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud